Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Fuji
US Department of Justice
UBS
Chubb
Chinese Patent Office
Argus Health
QuintilesIMS
Harvard Business School

Generated: August 20, 2018

DrugPatentWatch Database Preview

Genzyme Corp Company Profile

« Back to Dashboard

Summary for Genzyme Corp
International Patents:165
US Patents:8
Tradenames:4
Ingredients:4
NDAs:5
Drug Master File Entries: 9
Patent Litigation for Genzyme Corp: See patent lawsuits for Genzyme Corp

Drugs and US Patents for Genzyme Corp

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp FLUDARA fludarabine phosphate INJECTABLE;INJECTION 020038-001 Apr 18, 1991 DISCN Yes No ➤ Sign Up ➤ Sign Up
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes 8,642,608 ➤ Sign Up ➤ Sign Up
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No 8,642,608 ➤ Sign Up ➤ Sign Up
Genzyme Corp HECTOROL doxercalciferol CAPSULE;ORAL 020862-003 Jul 13, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up
Genzyme Corp HECTOROL doxercalciferol INJECTABLE;INJECTION 021027-001 Apr 6, 2000 AP RX Yes Yes ➤ Sign Up ➤ Sign Up
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No 7,173,038 ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Genzyme Corp

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme Corp HECTOROL doxercalciferol INJECTABLE;INJECTION 021027-001 Apr 6, 2000 5,707,980 ➤ Sign Up
Genzyme Corp FLUDARA fludarabine phosphate INJECTABLE;INJECTION 020038-001 Apr 18, 1991 4,357,324*PED ➤ Sign Up
Genzyme Corp HECTOROL doxercalciferol INJECTABLE;INJECTION 021027-002 Apr 6, 2000 5,602,116 ➤ Sign Up
Genzyme Corp HECTOROL doxercalciferol CAPSULE;ORAL 020862-002 Apr 23, 2004 5,602,116 ➤ Sign Up
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 6,414,148 ➤ Sign Up
Genzyme Corp HECTOROL doxercalciferol INJECTABLE;INJECTION 021027-001 Apr 6, 2000 5,602,116 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GENZYME CORP drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 0.5 mcg and 2.5 mcg ➤ Subscribe 2009-03-25
➤ Subscribe Capsules 1 mcg ➤ Subscribe 2010-02-12
➤ Subscribe Injection 2 mcg/mL, 2 mL ampules ➤ Subscribe 2007-10-15
➤ Subscribe Injection 2 mcg/mL, 1 mL in 2 mL vial ➤ Subscribe 2011-12-28

Non-Orange Book US Patents for Genzyme Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,855,830 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors ➤ Sign Up
8,779,163 Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors ➤ Sign Up
6,569,889 Amino ceramide-like compounds and therapeutic methods of use ➤ Sign Up
6,890,949 Amino ceramide-like compounds and therapeutic methods of use ➤ Sign Up
5,916,911 Amino ceramide--like compounds and therapeutic methods of use ➤ Sign Up
9,040,548 Quinazoline derivatives as VEGF inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Genzyme Corp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1244647/01 Switzerland ➤ Sign Up FORMER OWNER: ASTRAZENECA AB, SE
/2015 Austria ➤ Sign Up PRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119
2015 00035 Denmark ➤ Sign Up PRODUCT NAME: ELIGLUSTAT, EVENTUELT I FORM AF ET FYSIOLOGISK ACCEPTABELT SALT, HERUNDER ELIGLUSTAT (SOM TARTRAT); REG. NO/DATE: EU/1/14/974 20150119
C0048 France ➤ Sign Up PRODUCT NAME: VANDETANIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/11/749/002 20120217
00738 Netherlands ➤ Sign Up PRODUCT NAME: ELIGLUSTAT, OF FYSIOLOGISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/974 20150119
0150027 00161 Estonia ➤ Sign Up PRODUCT NAME: ELIGLUSTAAT;REG NO/DATE: EU/1/14/974 21.01.2015
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Cipla
Farmers Insurance
Argus Health
Mallinckrodt
Harvard Business School
Chinese Patent Office
Healthtrust
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.